Aesthetic distributor Merz has launched a dermal filler containing a combination of hyaluronic acid and glycerol called Belotero Revive.
The company explains that it is designed to improve hydration, elasticity and firmness of the skin to address the appearance of fine lines.
The newly-launched product was clinically assessed in a study involving 24 patients, where it was injected into the lower cheek area and results were assessed in an observation period of 36 weeks. It was reported that 100% of patients showed improved aesthetic results at week 12, more than 80% were satisfied with the treatment at week 24 and 90% would recommend it to friends.
Philip Burchard, CEO of Merz commented on the new Belotero launch, “Customer research and market trends make it clear that a new generation of patients is increasingly open to aesthetic medicine and actively looking for options to treat the first visible signs of ageing.”
He continued, “At Merz, we have a strong focus on researching and developing innovative and effective solutions that can be used to address both specific patient needs and new market trends in medical aesthetics. With Belotero Revive we are proud to be able to provide aesthetic practitioners with a new dermal injectable that can be used for both early intervention and beautifications.”
Merz has also launched a Belotero Revive campaign, which encourages patients to ‘show off the best version of themselves without a filter’ and hints at the influence of digital sphere on real-life moments. It is also designed to speak to the growing acceptance of aesthetic medicine in different age groups, while encouraging female consumers to make choices that bring out their own individuality and natural beauty, Merz confirms.
Belotero Revive is expected to launch in the UK in 2020.